[The experimental and clinical antitumor action of the interferon inducer larifan]. 1991

M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian

The paper presents the results of experimental and clinical studies on the antitumor effect of larifan. A statistically significant inhibition of growth of some continuous mouse tumors by larifan in a dose of 2.5 mg/kg given for 5-6 days and by a combination of larifan with an immunomodulator, inosiplex, tested on hepatoma XXIIa which has a rather low sensitivity to larifan. The antitumor effect of larifan may be due to interferon production and immunomodulating effect. Treatment with 0.05% larifan ointment of patients with cervical dysplasia of moderate degree resulted in a significant increase of previously diminished production of alpha-interferon after 10-14 vaginal tampons and clinical cure in 88% of cases. A course of 8-10-day larifan monotherapy given before radial therapy resulted in a considerable improvement in patients with cervical cancer of II-III stages, and subsequently, for 1 1/2-month combined radial therapy, no significant changes in production of alpha-IF were observed. At the same time, in patients with cervical cancer treated by radial therapy alone a significant decrease of alpha-IF production by blood mononuclears was observed by the end of therapy.

UI MeSH Term Description Entries
D007369 Interferon Inducers Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. Inducers, Interferon
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009930 Organic Chemicals A broad class of substances containing carbon and its derivatives. Many of these chemicals will frequently contain hydrogen with or without oxygen, nitrogen, sulfur, phosphorus, and other elements. They exist in either carbon chain or carbon ring form. Organic Chemical,Chemical, Organic,Chemicals, Organic
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
July 1990, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1994, Voprosy virusologii,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1993, Voprosy onkologii,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1983, Voprosy virusologii,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1977, Archivum immunologiae et therapiae experimentalis,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
February 1995, Anti-cancer drugs,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
November 1978, Cancer treatment reports,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1979, International journal of immunopharmacology,
M G Gasparian, and N G Dzhagatspanian, and R A Gevorkian, and L A Kamalian
January 1975, Voprosy onkologii,
Copied contents to your clipboard!